Videos
What are the current unmet needs?
Despite statins, there are significantly unmet clinical needs in cholesterol lowering treatment. Statin do not effectively treat more than 50% of people with Familial Hypercholesterolaemia (FH) and other patients have intolerable side effects, says Professor Erik Stroes.
read more »
PCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor
New disclosures show that inhibition of PCSK9 reduces Lp(a) cholesterol – an emerging risk factor for cardiovascular disease, according to US expert, Professor Henry Ginsberg.
read more »
Implications from TESLA for FH management
The investigational PCSK9 inhibitor evolocumab, promises to be an important new treatment for a rare but serious genetic disorder, homozygous familial hypercholesterolaemia, according to one of the investigators in the TESLA study, Professor Frederick Raal.
read more »
Do the PCSK9 monoclonal antibodies have neurocognitive effects
There is reassuring evidence of the neurocognitive safety of the monoclonal antibodies developed to reduce low density lipoprotein cholesterol (LDL-C) by targeting PCSK9, Professor Frederick Raal discusses this topic.
read more »
Unmet needs in children with FH
Identification and treatment to reduce low density lipoprotein cholesterol (LDL-C) of children with familial hypercholesterolaemia (FH) is vital to reduce the risk of cardiovascular death in early adulthood. FH is the most common genetic disorder in the world. Parents and healthcare professionals need to be…
read more »
ODYSSEY long term
Low density lipoprotein cholesterol (LDL-C) was reduced by 60% in patients treated an investigational PCSK9 inhibitor, Alirocumab in addition to statin therapy, for about 52 weeks in the ODYSSEY study. The lead investigator, Professor Jennifer Robinson discusses how this was translated into a reduction in…
read more »
Improving the management of the FH patient
Professor Raul Santos from Brazil says that the new therapies which inhibit PCSK9 to significantly reduce low density Lipoprotein Cholesterol (LDL-C) when given in addition to other cholesterol lowering drugs offer a very important advance in reducing cardiovascular risk in people with Familial Hypercholesterolemia (FH).
read more »
Familial hypercholesterolaemia: putting the patient first
Patients and their families must be proactively involved in the identification and treatment of people with familial hypercholesterolaemia (FH) – a group whose severely raised low density lipoprotein cholesterol (LDL-C) puts them at a very high risk of premature death. Founder and CEO of the…
read more »
FH in Argentina: Why the European Atherosclerosis Society FH Studies Collaboration (EAS-FHSC) is key
PCSK9 Forum caught up with Dr Pablo Corral, ICM Institute Medical Clinic, Buenos Aires, Argentina during the 83rd European Atherosclerosis Society (EAS) Congress in Glasgow, Scotland. The status of FH management in Argentina has improved over the last 2 years. There has been a new…
read more »
Implications from TESLA and early TAUSSIG studies with evolocumab
Results of clinical trials of the investigational therapy – evolocumab, a PCSK9 inhibitor will potentially change care of patients at a high risk of cardiovascular disease (heart attacks), by reducing their very high low density lipoprotein cholesterol (LDL-C) levels.
read more »Implications from TESLA and early TAUSSIG studies with evolocumab
Results of clinical trials of the investigational therapy – evolocumab, a PCSK9 inhibitor will potentially change care of patients at a high risk of cardiovascular disease (heart attacks), by reducing their very high low density lipoprotein cholesterol (LDL-C) levels. The Forum talks to Professor Gerald…
read more »
In your opinion, what are the optimum patient populations for PCSK9 monoclonal antibody therapy?
PCSK9 monoclonal antibodies offer very important new treatments to lowed low density lipoprotein cholesterol (LDL-C) in patients who cannot tolerate statins or whose LDL-C is inadequately reduced as well as those people with high LDL-C caused by Familial Hypercholesterolemia.
read more »
European Atherosclerosis Society Consensus Panel on statin-associated muscle symptoms: Professor Erik Stroes, Academic Medical Center, the Netherlands
PCSK9 Forum caught up with Professor Stroes at the 83rd Congress of the European Atherosclerosis Society (EAS), Glasgow 22-25 March, 2015 to discuss this recent EAS Consensus Panel paper. Statin-associated muscle symptoms (SAMS) were very much the hot topic at EAS Glasgow, reflecting the high…
read more »
Weighing the cost versus benefit of PCSK9-targeted therapy
PCSK9 inhibitors are the most important advance in cholesterol lowering treatments since the discovery of statin drugs, says Spanish vascular disease researcher, Professor Lluís Masana.
read more »
High cholesterol: an unmet need
Health authorities are failing to recognise that most patients do not achieve the cholesterol levels needed to prevent cardiovascular disease. Professor Lluís Masana says this must become a public health priority.
read more »
The role of PCSK9 inhibitors in FH
The low density lipoprotein cholesterol (LDL-C) lowering effects of evolocumab, a new PCSK9 inhibitor, in patients with familial hypercholesterolaemia (FH) are very encouraging, Dr Dirk Blom, University of Cape Town says. This will be very important in countries such as South Africa.
read more »
Lowering LDL-C: How low and for how long?
Treatment to reduce low density lipoprotein cholesterol (LDL-C) should be started in teenage years in people with very high risk of cardiovascular death or events e.g. heart attacks. There is substantial evidence showing significant benefits if LDL-C is reduced by about 50%, Professor Evan Stein…
read more »
Looking ahead with PCSK9 Education & Research Forum
Researchers and clinicians are enthusiastically expanding their knowledge of important new discoveries in cholesterol lowering therapies with PCSK9 inhibitors. Co-editor, Professor Henry Ginsberg, looks to the future.
read more »
LDL-C: how low should clinicians aim for?
Trials with monoclonal antibodies – PCSK9 inhibitors – will answer the question of how far should low density lipoprotein cholesterol (LDL-C) be reduced?
read more »
What are the patient priorities for PCSK9 inhibitors?
The low density lipoprotein cholesterol (LDL-C) lowering potency of the new PCSK9 inhibitors, creates exciting opportunities to effectively lower lipids in high risk patients, including those with familial hypercholesterolaemia (FH) for the first time. Professor Henry Ginsberg discusses the clinical potential of these new therapies.
read more »
